OM336-AIC-1001
OM336-AIC-1001: OM336 in Autoimmune Cytopenias
Trial summary:
An open-label, multicenter, ascending dose study, evaluating safety, tolerability, and PK/ADA of OM336 in autoimmune cytopenias.
Receptor status / problem studied:
Inclusion criteria
1) Active autoimmune cytopenia.
2) Relapsed/refractory after ≥1 prior treatment.
3) Body weight ≥ 55 kg.
4) Willing to comply with and study requirements and procedures.
Exclusion criteria
1) Previous treatment with a BCMA-targeted therapy.
2) Clinically significant infection within 3 months of screening.
3) Major surgery or splenectomy within 3 months of screening or planned during the study.
4) Pregnant or breastfeeding.
Open for recruitment
Trial Title
OM336-AIC-1001
Diagnosis
Immune Thrombocytopenia (ITP)
Type of trial
Pharmaceutical
Type of treatement
Haematology
Phase
I
Locations
Investigators
Principal Investigator